Georgia State University

ScholarWorks @ Georgia State University
Public Health Dissertations

School of Public Health

Summer 8-9-2016

Quality Improvement in Stroke Care and Its Impact: the Georgia
Coverdell Acute Stroke Registry Experience
Moges Ido

Follow this and additional works at: https://scholarworks.gsu.edu/sph_diss

Recommended Citation
Ido, Moges, "Quality Improvement in Stroke Care and Its Impact: the Georgia Coverdell Acute Stroke
Registry Experience." Dissertation, Georgia State University, 2016.
doi: https://doi.org/10.57709/8848854

This Dissertation is brought to you for free and open access by the School of Public Health at ScholarWorks @
Georgia State University. It has been accepted for inclusion in Public Health Dissertations by an authorized
administrator of ScholarWorks @ Georgia State University. For more information, please contact
scholarworks@gsu.edu.

GEORGIA STATE UNIVERSITY, SCHOOL OF PUBLIC HEALTH

QUALITY IMPROVEMENT IN STROKE CARE AND ITS
IMPACT: THE GEORGIA COVERDELL ACUTE STROKE
REGISTRY EXPERIENCE

by
MOGES SEYOUM IDO
MD, MS, MPH
A Dissertation Submitted to the Graduate Faculty
of
Georgia State University
in Partial Fulfillment of the Requirements for the Degree
DOCTOR OF PHILOSOPHY IN PUBLIC HEALTH

ATLANTA, GEORGIA
30303
JUNE 2016

QUALITY IMPROVEMENT IN STROKE CARE AND ITS IMPACT: THE GEORGIA
COVERDELL ACUTE STROKE REGISTRY EXPERIENCE

by

MOGES SEYOUM IDO, MD, MS, MPH

Approved by:

Committee Chair
Prof. Richard Rothenberg

Committee Member
Prof. Ike Okosun

Committee Member
Prof. Michael Frankel

Date : June 22, 2016

i

Author’s Statement Page

In presenting this dissertation as a partial fulfillment of the requirements for an advanced
degree from Georgia State University, I agree that the Library of the University shall make it
available for inspection and circulation in accordance with its regulations governing materials of
this type. I agree that permission to quote from, to copy from, or to publish this dissertation may
be granted by the author or, in his/her absence, by the professor under whose direction it was
written, or in his/her absence, by the Associate Dean, School of Public Health. Such quoting,
copying, or publishing must be solely for scholarly purposes and will not involve potential
financial gain. It is understood that any copying from or publication of this dissertation which
involves potential financial gain will not be allowed without written permission of the author.

___Moges Seyoum Ido_____________
Signature of Author

ii

TO MY PARENTS:
GHENET BALCHA WURGHI
SEYOUM IDO BORU

iii

Contents
Acknowledgment

vi

Illustrations

vii

ABSTRACT

1

Chapter I
Introduction

3

Quality Improvement

3

The Georgia Coverdell Acute Stroke Registry

6

Study Objectives

8

Chapter II
Participation in registry based quality improvement and its impact on patient outcome
Abstract

10

Introduction

12

Methods

13

Results

17

Discussion

18

Chapter III
Quality improvement performance measures vis-à-vis patient outcome
Abstract

27

Introduction

29

Methods

30

Results

33

Discussion

34

iv

Chapter IV
Long-term effectiveness of intravenous alteplase in acute ischemic stroke
Abstract

42

Introduction

44

Methods

44

Results

48

Discussion

49

Chapter V
Summary

55

References

59

Annex

67
Linkage between the Georgia Coverdell Acute Stroke Registry and the Georgia
Discharge Data System

v

ACKNOWLEDGMENT

I would like to thank my committee members Prof. Richard Rothenberg, Prof. Ike S Okosun and
Prof. Michael Frankel for their feedback and support that helped me understand the different
facets of my dissertation.

I do also acknowledge the Georgia Coverdell Acute Stroke Registry team and the participating
hospitals for their continuous effort to improve the quality of stroke care across the state of
Georgia and express my gratitude for providing me with access to their data.

vi

ILLUSTRATIONS
Figures
1. Flow diagram for patients included in the analysis of impact of quality improvement

40

2. Defect-free care and average composite measure by the number of performance measure acute
ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013

41

3. Median National Institute of Health stroke scale score by the number of performance measure
acute ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013

41

4. Flow diagram for patients included in the analysis effectiveness of intravenous alteplase

54

Tables
1. Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data of
the same calendar Year

22

2. Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data
from different calendar years

23

3. Agreement in the matching variables of the linked Georgia hospital discharge data and
Georgia mortality data

24

4. Characteristics of acute ischemic stroke patients (n = 50,579) cared for by Georgia Coverdell
Acute Stroke Registry participating and nonparticipating hospitals, Georgia Hospital Discharge
Data, 2006–2009, and Georgia Mortality Data, 2006–2010

25

5. Relative risk for death for Georgians with acute ischemic stroke, Georgia Hospital Discharge
Data, 2006–2009, and Georgia Mortality Data, 2006–2010

26

6. Performance measures endorsed by the CDC, the American Heart Association/American
Stroke Association and the Joint Commission

37

7. Characteristics of acute ischemic patients by defect-free care status, Georgia Coverdell Acute
Stroke Registry, 2008–2013

38

8. Relative risk of 1-year mortality and non-ambulating at discharge among acute ischemic
stroke patients by quality of care, Georgia Coverdell Acute Stroke Registry 2008-2013.

39

9. Characteristics of acute ischemic stroke patients eligible for IV alteplase and with complete
information (n=2925), Georgia Coverdell Acute Stroke Registry, 2008-2013
.
10. Relative risk of 1-year mortality and readmission by intravenous alteplase treatment status,
Georgia Coverdell Acute Stroke Registry 2008-2013

52

vii

53

ABSTRACT
QUALITY IMPROVEMENT IN STROKE CARE AND ITS IMPACT: THE GEORGIA
COVERDELL ACUTE STROKE REGISTRY EXPERIENCE

by

MOGES SEYOUM IDO, MD, MS, MPH

June 22, 2016

The Georgia Department of Public Health has been engaged in a registry-based quality
improvement initiative to monitor and improve the quality of stroke care. It is important to
evaluate effectiveness of the quality improvement initiative in order to expand the effort to other
sites or disease conditions. The studies, included in this dissertation, addressed whether acute
ischemic stroke patients cared for by hospitals participating in the Georgia Coverdell Acute
Stroke Registry (GCASR) had a better survival than those treated at other facilities, assessed
whether quality of care as measured by nationally accepted ten performance measures is
associated with improved patient outcome and evaluated the impact of intravenous alteplase
treatment on 1-year mortality.
Three data sources – GCASR, Georgia Discharge Data System and the death data – were
used for analyses. These data sources were linked applying both a hierarchical deterministic and
a probabilistic linkage methods. Survival after stroke incident was analyzed using the extended
Cox proportional hazard model. Generalized estimating equation (glimmix procedure) and
conditional logistic regression were applied, respectively, to assess the association of quality of
care and intravenous alteplase use with 1-year mortality.
1

Acute ischemic stroke patients treated at nonparticipating facilities had a hazard ratio for
death of 1.14 (95% confidence interval, 1.03–1.26; P-value = .01) after the first week of
admission compared with patients cared for by hospitals participating in the registry. Among
patients treated in GCASR-participating hospitals, patients who received the lowest and
intermediate quality care respectively had a 3.94 (95%CI: 3.27, 4.75; p-value <0.0001) and a
1.38 (95%CI: 1.12, 1.62; p-value=0.002) times higher odds of dying in one year compared to
those who got the best quality stroke care. Patients who were eligible but did not receive IV
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying within one
year than those who were treated with the thrombolytic agent.

The results strongly suggest that registry-based quality improvement effort has brought
significant improvements in ischemic stroke patients’ outcomes. Therefore, it is critical that
hospitals adopt a quality improvement strategy to change the process of care delivery for a better
patient outcome.

2

CHAPTER I

INTRODUCTION

Quality Improvement

Healthcare providers strive to improve the quality of patient care and enhance their
performance. The assessments and continuous systematic efforts to improve quality of care
constitute quality improvement.1 Quality improvement is data driven, focuses on patients’ need
and expectations, and works on processes and systems of healthcare delivery.1 In most healthcare
setups, particularly where multiple units play a role in the process of healthcare delivery, it
requires a team effort involving every unit of the organization to improve the quality of patient
care.
The Institute of Medicine (IOM) defines quality of care as “the degree to which health
services for individuals and populations increase the likelihood of desired health outcomes and
are consistent with current professional knowledge.”2 Quality of care encompasses every aspect
of healthcare – diagnostic, therapeutic and preventive – both in a clinical and community setup.
Delivery of a clinical care has three dimensions: the environment in which the care is provided
(the structure); the actual care including patient reception, diagnosis, treatment, preventive care
and discharge instruction; and the outcome in terms of patient health status, satisfaction, and
behavior and resource consumption.3 Measurement of the factors in each dimension of care
delivery may not be sufficient to evaluate quality of care unless they can be shown to relate to
indices of quality.
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The IOM’s definition implies that quality is inherent to any health service and the care
has to be congruent with the best available evidence-based practices and guidelines. Adherence
to these guidelines need to be monitored continuously to ensure that patients receive the best care
at all times. Measuring healthcare providers’ performance requires continuous systematic data
collection and analysis, and performance measures to assess whether the provider is attaining the
goal set for healthcare delivery process.

Despite rapid advances in medical science and technology, not all patients consistently
receive high quality clinical care. A study among American adults in 12 metropolitan cities
indicated that patients received only 55% of the recommended care.4 Almost two decades after
FDA approved the use of thrombolytics for ischemic stroke patients, only 12% of the patients
receive the treatment in Georgia.5 Thus, medical advances and the availability of resources do
not necessarily translate into provision of high quality care to all patients over time. It is,
therefore, necessary to design strategies for dissemination and broad scale application of
evidence based clinical practices. How states organize their healthcare system or how healthcare
providers set up delivery of care taking a system’s perspective becomes important in meeting
patients’ expectation and expectations of the community at large.

Replication and implementation of an intervention require demonstration of effectiveness
in a broader use. Despite evidence of effectiveness, hindrance to implementation could come
from lack of information about the new strategy on quality of care or from reluctance to accept
the new clinical care guidelines.6-8 Strong evidence demonstrating the effectiveness of an
intervention would facilitate buy-in from healthcare facilities and their practitioners. Therefore, it
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is essential to measure, evaluate and document the changes brought by interventions targeting
quality of care and its purported impact on patient outcomes.

Strategies to implement evidence based medicine has evolved from the optimistic passive
diffusion where we assume clinicians would adopt a new clinical practice if they are provided
with the information to a more active approach of quality improvement.9 The concept of quality
improvement is not unique for clinical care or healthcare in general; rather, the industrial sector
is the vanguard in implementing methods of quality improvement for better productivity
(efficiency) and ensuring product quality.10 Methods of quality improvement tried and tested in
other sectors have also been shown to be applicable in clinical care11,12 as well because the
ultimate target remains the same – better outcome in the most efficient way.

Studies have shown that implementation of quality improvement activities lead to
improvement in the process of care delivery and patient’s outcomes.13-23 These studies involved
healthcare facilities of different levels and various clinical conditions from infectious disease to
chronic conditions such as depression and diabetes mellitus. They documented improvements in
adoption of care processes and uptake of evidence-based guideline recommendations including
prescription of appropriate medications, reduction in unnecessary referrals, narrowing the gap in
gender and racial disparity in health outcomes, reducing complications, secondary disease
prevention and better patient outcomes in terms of disease control, readmission rate and
mortality.

Some studies, however, failed to demonstrate significant improvement both in patient
care process and outcome resulting from QI activities.24-26 A review of literature on the impact of
quality improvement initiatives concluded that the effect of a quality improvement undertaking
5

cannot be predicted with certainty.24 The reviewers examined 72 papers from 1,101 published on
quality improvement from 1995 to 2006, and were only able to show that quality improvement
collaborative would improve care process, organizational performance, access to care and
consumer satisfaction but not the outcome. Therefore, it is important to evaluate such initiatives
using outcome measures both for the purpose of long-term, large scale implementation and for
identifying components of the quality improvement initiative with the greatest relationship to
those outcomes, even if they were launched initially based on available scientific evidences.

In the context of clinical care, ensuring clinicians adhere to evidence-based clinical
guidelines is part of a quality improvement task. Guidelines usually are institution-based, but in
some cases there are guidelines developed by experts or professional associations that are also
endorsed and recommended by national institutions. It is expected that such guidelines would be
readily disseminated to healthcare providers and easily adopted, although the environment in
which the care is provided and the processes involved in implementing national guidelines must
be considered. However, the basic question –whether or not adherence to clinical guidelines in
stroke care results in better patient outcome – remain unanswered.

The Georgia Coverdell Stroke Registry
Stroke is the fifth leading cause of mortality in the United States.27 Every year, around
800,000 people develop acute stroke28 and about 70% of the survivors develop some residual
disability including neurological deficit, speech disorder, cognitive deficit or psychological
disorder such as depression.29 Stroke not only affects the individual patient but adds economic and
emotional burden to their caregivers and the community at large.30,31 In the United States, the direct
and indirect costs of stroke amounted to 36.5 billion dollars in 2010.28
6

In 2001, the United States Congress directed the Centers for Disease Control and
Prevention (CDC) to establish a state-based acute stroke registry to measure and monitor the
quality of acute stroke patient care.32 After three years of piloting, the state of Georgia received a
grant to set-up a registry which is currently housed in the Department of Public Health (DPH).
Since then, DPH, in collaboration with its partners, has been assisting more than 60 hospitals to
improve the quality of stroke patient care. Different size hospitals ranging from critical access to
large teaching hospitals participate in the registry; currently, about 80 percent of stroke patients
are treated at GCASR participating hospitals.

A wealth of scientific evidences shows that improvement in specific elements of clinical
care could result in better patient outcome.33 The Georgia Coverdell Acute Stroke Registry
(GCASR) encourages hospitals to adopt a quality improvement program and provides technical
assistance through regular trainings, workshops, site visits and direct one-on-one consultations,
data feed-back, mentorship and sharing the best practices to ensure that every patient in Georgia
receives the best evidence-based clinical care.
The Institute of Medicine’s definition of quality of care puts emphasis on health outcome
as indicators of quality, although information on the type, level and amount of healthcare
provided to the community is also essential. Outcome measures may not be as sensitive as
process measures in showing immediate changes made in quality improvement initiatives;
however, they are necessary to show that the change in process measures results in benefits to
patients.34
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STUDY OBJECTIVES

GCASR has registered significant improvements in the quality of care provided in
participating hospitals.35,36 Based on the 2005-2009 hospital discharge data, ischemic stroke
patients cared for by GCASR hospitals had a 64% higher odds (OR=1.64) of receiving
intravenous thrombolysis. However, it needed to be seen whether patients cared for by hospitals
participating in GCASR had better outcome and if this improvement in patient outcome could be
attributed to the quality improvement measures undertaken by the participating hospitals. The
main objective of this study, therefore, is to assess the direct impact of the quality improvement
program on short and/or long term outcomes – ambulatory status at discharge, readmission and
death.

Objective 1.

Do acute ischemic stroke patients treated at GCASR hospitals have a better
survival than patients cared for by non-participating hospitals?

Objective 2.

Does quality improvement as measured by the ten performance measures reduces
the 1-year mortality of acute ischemic stroke patients?

Objective 3.

Does intravenous alteplase affect mortality among acute ischemic stroke patients?

The results will help to expand the program to non-participating hospitals in Georgia and
for other states to learn from and replicate Georgia’s experience. The studies required linking
three data sources – the GCASR data, the Georgia Discharge Data system (GDDS - hospital
discharge data) and the Death Records – related to the care and outcome of stroke patients in
Georgia. GCASR and GDDS data from 2008 to 2013 and death data from 2008 to 2014 were
linked and analyzed. The data sources have variables on patient demography, disease status,
8

treatment, facility and event-related information. This experience of linking registry and
administrative data will serve as a blue print for evaluation of other public health programs based
on clinical care.

9

CHAPTER II

Administrative Data Linkage to Evaluate a Quality Improvement Program in Acute
Stroke Care, Georgia, 2006 – 2009
ABSTRACT

Introduction

Tracking the vital status of stroke patients through death data is one approach to assessing
the impact of quality improvement in stroke care. We assessed the feasibility of linking Georgia
hospital discharge data with mortality data to evaluate the effect of participation in the Georgia
Coverdell Acute Stroke Registry on survival rates among acute ischemic stroke patients.

Methods

Multistage probabilistic matching, using a fine-grained record integration and linkage
software program and combinations of key variables, was used to link Georgia hospital discharge
data for 2005 through 2009 with mortality data for 2006 through 2010. Data from patients
admitted with principal diagnoses of acute ischemic stroke were analyzed by using the extended
Cox proportional hazard model. The survival times of patients cared for by hospitals
participating in the stroke registry and of those treated at nonparticipating hospitals were
compared.

Results

Average age of the 50,579 patients analyzed was 69 years, and 56% of patients were
treated in Georgia Coverdell Acute Stroke Registry hospitals. Thirty-day and 365-day mortality
10

after first admission for stroke were 8.1% and 18.5%, respectively. Patients treated at
nonparticipating facilities had a hazard ratio for death of 1.14 (95% confidence interval, 1.03–
1.26; P-value = .01) after the first week of admission compared with patients cared for by
hospitals participating in the registry.

Conclusion

Hospital discharge data can be linked with death data to assess the impact of clinicallevel or community-level chronic disease control initiatives. Hospitals need to undertake quality
improvement activities for a better patient outcome

.
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INTRODUCTION

Assessing the impact of chronic disease programs and the quality of clinical care for
patients with chronic diseases is essential to identify areas for improvement in care and to
demonstrate the level and nature of improvements already made.37 The American Heart
Association/American College of Cardiology Working Group on Quality of Care and Outcomes
Research in Cardiovascular Disease and Stroke advocates measuring the short-term and longterm outcomes of quality of care for stroke patients as a way of determining the impact of related
chronic disease programs.38 Tracking the vital status of patients with chronic disease, who may
be seen at different health facilities, by using death data is a promising method for assessing the
overall quality of care for chronic diseases.37

Administrative data such as hospital discharge data and death data are great resources for
public health studies.39–41 These are population-based databases that can be used to assess the
quality of stroke care because they include all population groups. Administrative data are easy to
access, and they provide longitudinal information for passive follow-up and trend analyses.

The Georgia Coverdell Acute Stroke Registry (GCASR) is a part of a national stroke
registry program, the Paul Coverdell National Acute Stroke Registry. The national registry has
the long-term goal of reducing premature deaths attributable to stroke and preventing stroke
disability and recurrent stroke through ensuring the highest quality of acute stroke care to all
Americans. GCASR was launched by the Georgia Department of Public Health in 2005 in
partnership with other stakeholders. We sought to assess the feasibility of linking mortality data
from the Georgia Department of Public Health Office of Vital Records with hospital discharge
data from the Georgia Hospital Association’s Georgia Discharge Data System (GDDS) and to
12

evaluate the impact of participation in a state-based registry program on survival of patients with
acute ischemic stroke.

METHODS

Georgia death records and Georgia hospital discharge data

The Georgia Department of Public Health Office of Vital Records is responsible for
collecting information about deaths among Georgians by using the death certificates. The death
certificate contains information on individuals’ demographic characteristics, residence,
underlying possible causes of death, location of death, and death date. Each year, more than
67,000 Georgians die, and 98% of the deaths occur within the state of Georgia.

The GDDS is housed at the Georgia Hospital Association and has information on all
inpatients discharged from nonfederal short-stay hospitals in Georgia. GDDS gathers more than
a million records per year. GDDS and mortality data share common variables including age, sex,
race, residence information, and a quasi-unique subject identifier (LONGID) that facilitates the
data linkage.

The feasibility of data linkage is based on the assumption that the variable LONGID was
sufficiently specific to distinguish each subject in the data sources. The LONGID is a 15-digit
alphanumeric unique code created from letters of patients’ first and last names, birth date, and
sex. We tested accuracy of data linkage by using data from GDDS for 1,494 Georgia patients
who were admitted to a hospital for acute stroke and who died as a result (International
Classification of Diseases, Ninth Revision [ICD-9]) codes 430–436) in 2006 and for 3,598
patients with similar age characteristics (patients with malignant neoplasm of respiratory and
13

intrathoracic organs: ICD-9 codes 160–165) but who were alive in 2006. Patients with similar
age characteristics were chosen because personal name patterns in a given community may
change through time.

The test data set was then linked with the Georgia mortality data for 2006 by using a
multistage deterministic and probabilistic matching algorithm and various combinations of key
variables (Table 1 and Table 2). We used fine-grained record integration and linkage software
for matching, and we excluded duplicate entries using the LONGID, admission and discharge
dates, and facility codes.42 Degrees of linkage between hospital discharge data and mortality data
were determined (Table 3).
Assessment of impact of stroke registry – survival analysis

We used the 2005 through 2009 GDDS and the 2006 through 2010 Georgia Office of
Vital Records mortality data to examine the survival rates of acute ischemic stroke patients.
Patients admitted to nonfederal acute care and critical access facilities with the principal
diagnosis ICD-9 codes 433 and 434 were identified and linked to the death data. Death and
survival time from the index admission date, regardless of the underlying cause of death, were
the outcome variables. We believe that care in the first few hours after stroke symptom onset
determines the stroke patient’s subsequent health condition, so we attributed the outcome to the
facility of first stroke admission. Patients were labeled to have had a first stroke admission in
2006 if they were not admitted for any type of stroke, ICD-9 codes 430–438, in 2005.

We defined enrollment in GCASR if the hospital actively participated in data entry and
quality improvement activities. We considered patients to have had stroke care by a GCASR
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facility if the hospital in which patients were admitted was enrolled in the registry. Patients who
were treated at any time before a facility was enrolled or after it withdrew its participation were
counted as patients treated by a non-GCASR hospital. We included patient’s sociodemographic
characteristics such as age, sex, race, insurance status, and length of hospital stay, and hospital
features including number of beds and location as covariates in the analysis. On the basis of the
number of beds, we classified hospitals as small (<100 beds), medium-small (100–249 beds),
medium-large (250–399 beds) and large hospitals (≥400 beds). We used the Rural-Urban
Commuting Area classification of location to classify hospitals geographically into metropolitan
(codes 1–3) and nonmetropolitan (codes >3).43

Comorbidities were included in the analyses to adjust for disease severity. We used the
Healthcare Cost and Utilization Project software from the Agency for Healthcare Research and
Quality (US Department of Health and Human Services) to define comorbidities for each patient
based on the ICD-9 codes in the hospital discharge data.44,45 Patients’ readmission status before
either the end of the follow-up period or the patient’s death was captured from the hospital
discharge data, and we classified patients as either not having been readmitted, readmitted to the
same hospital, or readmitted to a different hospital. If patients were admitted to a different
hospital within a day after their index or first admission date we considered their status as a
transfer rather than a readmission, and they were excluded from the analysis. All the variables
used in the analyses refer to what was documented at the first stroke admission except for the
date of death. To have stable estimates, we excluded stroke patients from hospitals with fewer
than 15 patients over the study period.

15

Statistical analysis

We analyzed the data by using SAS for Windows (version 9.3, SAS Institute, Inc). We
assessed the sensitivity of the linkage procedure based on the proportion of stroke-related inhospital deaths that were captured by the 2006 Georgia vital records mortality data. We
determined specificity by the proportion of subjects who were admitted in 2007 having a
malignant neoplasm of the respiratory organs that were linked to any of the records in the 2006
death file. We assessed patient and hospital characteristics descriptively and tested differences
between patients treated at GCASR participating and nonparticipating hospitals using χ2 tests for
nominal variables and Wilcoxon tests for quantitative variables.

We assessed the proportional hazard assumption graphically and through the goodnessof-fit test for correlation between the Schoenfield residuals and failure time.46 We repeated the
graphic assessment using the log–negative log of survival curves after adjusting for covariates.
The GCASR participation variable did not satisfy the proportional hazard assumption. Thus, we
analyzed survival time in correlated data using the extended Cox proportional hazard model with
the robust sandwich estimate option to estimate the marginal covariate effects. We performed the
analysis with and without censoring at 1 year. Results are presented indicating the hazard ratio
for death in the first year after the seventh day of the first stroke admission date by different
patient and hospital characteristics, including participation in GCASR.

16

RESULTS

Data linkage test for accuracy

Of the 1,494 acute stroke patients with an in-hospital death recorded in the 2006 hospital
discharge data, 1,381 (92.4%) were identified in the 2006 death data, whereas none of the 3,598
patients with malignant neoplasm of respiratory and intra-thoracic organs diagnosed in 2007
were linked to the 2006 death data. Agreements between hospital discharge records and death
data were high (>91%) for demographic variables, facility (93.6%), and discharge or death dates
(92.6%) (Table 3).

Impact of participation in state-based stroke registry: survival analysis

From the initial 50,937 patients listed, 358 were excluded because 269 were considered
transfers and 89 were from hospitals with fewer than 15 cases. Analysis was performed for
50,579 acute ischemic stroke patients (Table 4) admitted to 131 acute care and critical access
hospitals in Georgia to assess the impact of participation in GCASR during 2006 to 2009. Most
(52%) were women, and whites accounted for two-thirds (66%) of the patients. The mean age for
first stroke admission was 69 years. Most (64%) had Medicare as their principal health insurance
coverage. The median hospital length of stay was 3 days.

GCASR-participating hospitals treated 56% of the ischemic stroke patients (n = 28,077),
and there were no statistical differences in age, hospital length of stay, proportion of various
racial groups, or proportion of subjects with insurance coverage between patients treated at
GCASR and non-GCASR hospitals (Table 4). However, non-GCASR hospitals were more likely
to see female stroke patients, have less than 100 beds, to be in nonmetropolitan areas, and record
17

more stroke-related deaths at 30 and 365 days following stroke admissions. The overall mortality
at 30 days and 365 days after the first admission were 8.1% and 18.5%, respectively.

The extended Cox model indicated that patients treated at non-GCASR hospitals had a
hazard ratio of 1.14 (95% confidence interval [CI], 1.03–1.26) from the eighth day after
admission to 1 year after admission (Table 5). A similar hazard ratio (1.13; 95% CI, 1.04–1.22)
was observed when no cutoff date was applied. Similarly, older patients and those treated in
nonmetropolitan hospitals had a higher hazard ratio than their counterparts. Patients with a
private insurance or self-pay had a lower hazard ratio than did Medicare patients. In addition,
hospitals with fewer than 100 beds and longer hospital stays for patients were independently
associated with subsequent death (Table 5).

DISCUSSION

Acute ischemic stroke patients cared for by hospitals participating in GCASR had a better
outcome than their counterparts in nonparticipating hospitals. This study found a modest (14%)
increase in the hazard ratio for death in the first year for patients treated at non-GCASR
participating facilities. Several studies have shown that quality improvement efforts result in
improved stroke patient care.47–50 This study, however, demonstrated that a state-based initiative
based on the collaborative effort of professionals who are willing to share their expertise and
exchange best practices results in tangible benefit to the community served.

Patients treated at non-GCASR facilities continued to have the same hazard ratio
throughout their follow-up time, indicating perhaps that the clinical care provided to patients at
their first stroke episode influenced their risk of mortality in the subsequent years. Regardless of
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whether hospitals participated in the GCASR, patient outcomes throughout Georgia improved
with time. Compared with patients who had an acute ischemic stroke in 2009, patients during
2006 through 2007 had a 9% higher risk of dying during the first year after the index admission.
Development of new treatment guidelines and their implementation by health care providers may
have contributed to the reduction in mortality; however, it is impossible to rule out a possible
spillover effect of the GCASR initiatives to nonparticipating facilities.

There was no meaningful difference in outcomes among hospitals of different size except
for small hospitals (<100 beds) where patients had a 17% higher risk of mortality. Hospitals
participating in GCASR tended to be metropolitan and larger, and although our analyses adjusted
for these 2 variables, differences attributable to other variables between the 2 hospital groups
cannot be ruled out. It is not possible, thus, to associate the reduction in hazard ratio among the
GCASR hospitals entirely to the quality improvement initiatives undertaken by the registry. In
future studies, linking the registry data (where interventions received by patients are
documented) to the hospital discharge and death data will be helpful to associate the clinical care
information with patient outcome.

The yield from the linkage procedure was sufficient to assess the impact of the quality
improvement program. There would be patients who died but were not picked by the matching
procedure; however, failure to link was not related to the type of hospital where patients were
treated in the test data set. Failure to link gives a lower estimate of the actual mortality but does
not introduce bias in the study’s effect measure. Studies elsewhere reported different rates of
mortality for ischemic stroke.51–55 The mortality at 1 month poststroke admission ranges from
9% in Australian and Israeli studies to 17% in a Rochester, Minnesota, study. Also, the 1-year
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mortality has been reported to vary from less than 10% in Japanese and Taiwanese studies to
29% in the Minnesota study. The observed differences may be due to variations in study
methodology, population characteristics, and quality of patient care. The 1-year mortality
estimate observed in this analysis (18.5%) lies between extreme values that have been reported
by other investigators, thus indicating that the linkage procedure was sufficiently sensitive and
may even be a reasonable approach to estimate mortality and survival rates across the course of
stroke patient care. We believe our estimates may be lower than expected rates because the data
linkage may not have captured all patients who died in the given period, particularly those who
died outside the state of Georgia.

This study has limitations, some of which are inherent to any method that assesses the
effect of a quality improvement intervention. It is difficult to define the time when the effect of
such an intervention wanes, and several factors contribute to the overall well-being of a patient
through time. Survival of acute ischemic stroke patients depends on factors such as patient and
hospital characteristics, the time from symptom onset to arrival at the hospital, disease severity,
the quality of service received from the health care facility on first encounter, the quality of
rehabilitation services, and the quality of life once the patient is discharged from a hospital. This
analysis took into account most of the prehospital discharge factors except for time elapsed
between symptom onset and arrival at the hospital. In addition, we did not have information on
postdischarge rehabilitation and quality of life.

Although administrative data may lack consistent case definitions from one data set to
another and the use of ICD-9 codes may not capture all possible acute stroke patients, the effect
of misclassification is minimal in studies addressing the impact of hospitals’ participation in a
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quality improvement registry, because misclassifications are more likely to be non-differential
and would only reduce the effect measure toward the null value. Moreover, this study may not
have completely captured disease severity, which is the main predictor of mortality. Different
indices, including the National Institute of Health Stroke Scale, have been suggested by
researchers to predict mortality, but there is no consensus index.56–60 Each one has its own merit
in terms of feasibility of data collection, availability for data collection, and discriminatory
power of fatal outcome. Several studies used the comorbidity measure, initially developed by
Elixhauser et al44 in various disease conditions,61–66 and Zhu and Hill have demonstrated its
usefulness in stroke as well.67. It is, thus, reasonable and practical to use comorbidity measures to
account for disease severity.

State-based hospital discharge data and death data can be linked and are excellent for
estimating survival or risk for mortality, outcome measures that are helpful to assess the impact
of clinical-level or community-level chronic disease control initiatives. The results of this study
show that participation in a state-based stroke registry for improving the quality of care is
associated with reduced mortality from acute ischemic stroke. Thus, hospitals should be
encouraged either to participate in a structured program of quality improvement such as statebased registries or undertake their own quality improvement to provide the best possible
evidence-based care to their patients for a better outcome.
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Table 1. Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data of
the same calendar Year
Linkage Step

Step I

Step II

Linking Variable

Condition
Weight,a%

Acceptance
Level,b%

LONGIDc

Edit distance (0.05/0.15d)

70

Residence county

Equal fields Boolean distance

15

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

Namee

Edit distance (0.15/0.3)

40

Birth date

Date distance (±0 d)

30

Discharge date

Date distance (±0 d)

20

Residence zip codef

Equal fields Boolean distance

10

Namee

Edit distance (0.15/0.3)

40

Age, y

Numeric distance (±0)

10

Date distance (±0 d)

20

Equal fields Boolean distance

15

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

Birth date

Date distance (±0 d)

35

Discharge date

Date distance (±0 d)

25

Residence county

Equal fields Boolean distance

25

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

80

80

Discharge date
Step III
Residence zip code

Step IV

Distance Metric
(Approve/Disapprove Level)

f

a: Proportional weight for each element in the linkage step.
b: Total match score at which records are considered to be linked.
c: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex.
d: The proportion of mismatched characters used to determine whether the records are considered to be linked.
e: Refers to a 6-digit code derived from names.
f: 5-digit zip code.
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95

100

Table 2. Algorithm for merging the Georgia Discharge Data System with the Georgia mortality data from
different calendar years
Linkage Step

Step I

Step II

Step III

Linking Variable

Distance Metric
(Approve/Disapprove Level)

Condition
Weight,a%

Acceptance
Level,b%

LONGIDc

Edit distance (0.05/0.15)

70

Residence county

Equal fields Boolean distance

15

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

Named

Equal fields Boolean distance

40

Birth date

Date distance (±0 d)

30

Residence zip codee

Equal fields Boolean distance

15

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

Named

Edit distance (0.15/0.3)

40

Age

Numeric distance (±0)

30

Residence county

Equal fields Boolean distance

15

Race

Equal fields Boolean distance

10

Sex

Equal fields Boolean distance

5

a: Proportional weight for each element in the linkage step.
b: Total of condition weights at which records are considered to be linked.
c: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex.
d: Refers to a 6-digit code derived from names.
e: 5-digit zip code.
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80

81

100

Table 3. Agreement in the matching variables of the linked Georgia hospital discharge data and Georgia
mortality data
Agreement, %
Variable

Test Data and 2006
Death Data

2006–2009 Hospital
Discharge and 2006–
2010 Death Data

LONGIDa

85.8

91.3

Birth date

94.5

96.2

Nameb

91.9

98.3

Sex

99.2

99.8

Age

98.1

—d

Race

95.2

96.8

Residence county

91.0

88.3

Residence zip codec

62.0

62.6

Facility

93.6

—d

Discharge date or date of death

92.6

—d

a: 15-digit alphanumeric code created from letters of patients’ first and last names, birth date, and sex.
b: Refers to a 6-digit code derived from names.
c: 5-digit zip code.
d: Not all records are expected to match.
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Table 4. Characteristics of acute ischemic stroke patients (n = 50,579) cared for by Georgia Coverdell
Acute Stroke Registry participating and nonparticipating hospitals, Georgia Hospital Discharge
Data, 2006–2009, and Georgia Mortality Data, 2006–2010

Characteristics
Age, y, mean (SD)
Sex, n (%)
Male
Female
Race, n (%)
White
Black
Other
Primary insurance coverage, n (%)
Medicare
Medicaid
Private
Self-pay
All others
Length of stay, d, median (interquartile range)
Hospital size, n (%)
<100 beds
100–249 beds
250–399 beds
≥400 beds
Hospital location, n (%)c
Metropolitan
Nonmetropolitan
Calendar year, n (%)
2006
2007
2008
2009
No. (%) of deaths
Discharge
30 days
365 days
End of follow-up

All Hospitals
68.7 (13.9)

Treatment Location
Non-GCASR
GCASR
Hospitals
Hospitalsa
68.2 (13.9)
69.3 (13.9)

24,494 (48.4)
26,085 (51.6)

13,948 (49.7)
14,129 (50.3)

10,546 (46.9)
11,956 (53.1)

33,619 (66.5)
15,695 (31.0)
1,265 (2.5)

18,813 (67.0)
8,445 (30.1)
819 (2.9)

14,806 (65.8)
7,250 (32.2)
446 (2.0)

32,438 (64.1)
2,877 (5.7)
10,329 (20.4)
3,607 (7.1)
1,328 (2.6)
3.0 (2–6)

17,531 (62.4)
1,687 (6.0)
6,088 (21.7)
2,097 (7.5)
674 (2.4)
2.8 (1.3–5.4)

14,907 (66.3)
1,190 (5.3)
4,241 (18.8)
1,510 (6.7)
654 (2.9)
3.2 (1.7–5.6)

70 (53.4)
29 (22.1)
15 (11.5)
17 (13.0)

22 (36.7)
11 (18.3)
12 (20.0)
15 (25.0)

48 (67.6)
18 (25.4)
3 (4.2)
2 (2.8)

62 (47.3)
69 (52.7)

40 (66.7)
20 (33.3)

22 (31.0)
49 (69.0)

12,331 (24.4)
12,959 (25.6)
12,849 (25.4)
12,440 (24.6)

4,743 (16.9)
7,175 (25.5)
7,972 (28.4)
8,187 (29.2)

7,588 (33.7)
5,784 (25.7)
4,877 (21.7)
4,253 (18.9)

1,940 (3.8)
4,114 (8.1)
9,350 (18.5)
14,699 (29.1)

1,000 (3.6)
2,105 (7.5)
4,740 (16.9)
7,281 (25.9)

940 (4.2)
2,009 (8.9)
4,610 (20.5)
7,418 (33.0)

P-Valueb
.12
<.001

.63

.31

.80

<.001

<.001

<.001

.08
<.001
<.001
<.001

Abbreviation: GCASR, Georgia Coverdell Acute Stroke Registry; SD, standard deviation.
a: Non-GCASR hospitals are those that never participated in GCASR from 2006 through 2009.
b: χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively.
c: Based on Rural-Urban Commuting Area classification of location to classify hospitals geographically as metropolitan (codes 1–
3) or nonmetropolitan (codes >3)7.
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Table 5. Relative risk for death for Georgians with acute ischemic stroke, Georgia Hospital Discharge
Data, 2006–2009, and Georgia Mortality Data, 2006–2010
Hazard Ratioa in the First Year Post Stroke Admission
Characteristic
Estimate (95% CI)
Location of treatment
Hospital not participating in GCASR
Hospital participating in GCASR
Sex
Male
Female
Age group, y
≥80
65–79
45–64
<45
Race
Other
White
Primary insurance coverage
Medicaid
Private
Self-pay
All others
Medicare
Length of stay, d
Hospital size, n (%)
<100 beds
100–249 beds
250–399 beds
≥400 beds

1.14 (1.03–1.26)
1 [Reference]
0.93 (0.89–0.98)
1 [Reference]

Hospital locationc
Nonmetropolitan
Metropolitan
Calendar year
2006
2007
2008
2009

P-Valueb
.01

.004

5.45 (4.53–6.56)
2.18 (1.83–2.62)
1.34 (1.14–1.57)
1 [Reference]

<.001
<.001
<.001

1.03 (0.96–1.11)
1 [Reference]

.36

1.06 (0.94–1.19)
0.75 (0.67–0.84)
0.62 (0.51–0.75)
0.91 (0.80–1.19)
1 [Reference]
1.017 (1.013–1.022)

.35
<.001
<.001
.84

1.17 (1.02–1.33)
1.04 (0.92–1.18)
1.05 (0.91–1.21)
1 [Reference]

.02
.54
.48

1.11 (1.03–1.21)
1 [Reference]

.009

1.09 (1.02–1.18)
1.09 (1.02–1.17)
1.02 (0.95–1.09)
1 [Reference]

.02
.007
.64

<.001

Abbreviation: CI, confidence interval; GCASR, Georgia Coverdell Acute Stroke Registry.
a: Adjusted for comorbidities.
b: χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively.
c: Based on Rural-Urban Commuting Area classification of location to classify hospitals geographically as metropolitan (codes 1–
3) or nonmetropolitan (codes >3).7
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CHAPTER III

Quality of Care and Its Impact on One Year Mortality: the Georgia Coverdell Acute
Stroke Registry
Abstract

Introduction

Although performance measures to monitor the quality of acute stroke care exist, their
utility in measuring long-term outcomes is uncertain. This study assessed the 1-year mortality of
acute ischemic stroke patients cared for by hospitals participating in the Georgia Coverdell Acute
Stroke Registry.

Methods

The 2008-2013 Georgia Coverdell Acute Stroke Registry data were linked with hospital
discharge and death data using both hierarchical deterministic and probabilistic linkage
procedures. Delivery of care components related to ten nationally-approved performance
measures were used to define whether patients received quality care. Defect-free care and
composite measure methods were used to measure the quality of care. A generalized estimating
equation was applied, accounting for correlation at hospital level and taking hospital as a random
variable to assess the effect of quality of care on 1-year mortality.

Results
“Defect-free care” was positively associated with increased mortality; however, it was
also associated positively with stroke severity. The composite measure showed that patients who
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received the lowest and intermediate quality care, respectively, had a 3.94 (95%CI: 3.27, 4.75; pvalue <0.0001) and a 1.38 (95%CI: 1.12, 1.62; p-value=0.002) times higher odds of dying in one
year compared to those who got the best quality stroke care.

Conclusion

Data from the Georgia Coverdell Acute Stroke registry suggest that the defect-free care
measure is not helpful in assessing the impact of quality improvement activities. However, the
composite measure indicated that hospitals should be encouraged to implement quality
improvement activities for better long-term stroke patient outcome.
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INTRODUCTION

A wealth of scientific evidence shows that improvement in specific elements of clinical
stroke care could result in better patient outcomes.33 The Centers for Disease Control and
Prevention (CDC), the American Heart Association, and the Joint Commission have identified
ten specific elements of clinical care and developed associated indicators (Table 6) to measure
the quality of stroke care.32,33 Not every component of stroke care is indicated for all stroke
patients; rather, patients receive care based on their specific needs. A patient who received all
indicated care components is said to have had a “defect-free care,” an indicator that helps to
monitor progress in the quality of stroke care delivery.

The Georgia Coverdell Acute Stroke Registry (GCASR) was established by the Georgia
Department of Public Health, in collaboration with its partners and funded by CDC, to measure,
monitor, and improve the quality of acute stroke care across the state. Hospitals participating in
GCASR have shown significant improvement in the process of stroke patient care and delivery
of defect-free care.34,36 Nevertheless, improvement in the process of care delivery may not
necessarily translate into improvement in patient outcomes.24-26 Hence, the objective of this study
was to assess whether quality improvement as measured by defect-free care or a composite
measure is associated with improved short- and long-term outcomes among acute ischemic
stroke patients.
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METHODS

Data Sources and Linkage

This is a retrospective cohort study of acute ischemic stroke patients cared for by
GCASR-participating hospitals during 2008-2013. We used three data sources – the GCASR
data, the Georgia Discharge Data System (GDDS) and the Georgia death data. We linked the
GCASR and GDDS data using a hierarchical deterministic linkage procedure (sensitivity 87%
and positive predictive value 96%); the output was then linked with the death data applying a
probabilistic linkage approach (sensitivity 92% and specificity 100%). The probabilistic linkage
procedure and its yield is described previously68, and details on the deterministic linkage
procedure are provided as Annex. The Fine-Grained Record Integration and Linkage software
program version 2.1.5 was used to link the three data sources were linked stepwise using.42

Patients from the stroke registry with clinical diagnosis of acute ischemic stroke in 2008–
2013 were included in this study. We had 45,727 records with a clinical diagnosis of acute
ischemic stroke in the initial GCASR data list. Of these, 41,216 were linked with GDDS data but
only 39,331 had the data element critical for linking with the death data. Excluding the
readmissions, we had 36,043 subjects eligible for follow-up, and 35,028 were eligible for, at
least, one evidence-based stroke care component. We excluded from the analysis patients with
undocumented time of symptom onset because 59% of the observations have missing value
(Figure 1).
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Defect-free Care Measure

Patients were classified as having had a defect-free care if they received all elements for
which they were eligible as specified by the ten performance measures (Table 6). Defect-free
care does not take into account the number of care components patients are eligible to receive.
Thus, a patient who is eligible for three care components and received all is declared as having
had a defect-free care while a patient who received seven out of eight indicated care components
is identified as not having had a defect-free care.

Composite Measure

A composite measure, taking the proportion of indicated care components a patient
received, is an alternative measure of quality of care.47,69 However, it doesn’t fully account for
the number of indicated care components because delivery of eight out of eight would have the
same composite measure of 100% as providing three out of three. Thus, we weighted the
composite measure by the natural logarithm of the total number of indicated care components.
The care requiring eight elements will have a higher weight [ln(8)=2.0794] than the one with
three indicated care components [ln(3)=1.0986]. Patients were grouped in tertiles based on their
weighted composite measures. Those in the 1st terile with the lowest weighted composite
measure were considered to have had, relatively, the lowest quality of care; those in the 2nd tertile
represented an intermediate and patients in the 3rd tertile represented the best quality of stroke
care.
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Statistical Analyses
All analyses were done using SAS version 9.3 (SAS Institute, Inc., Cary, NC). Quality
of stroke care as measured by defect-free care or the composite indicator was the main predictor
of outcome. Death from any cause within 365 days from index admission and ambulatory status
at discharge were the outcomes of interest. We classified ambulatory status at discharge into two
groups: unable to walk, and walking with or without assistance from another person. Those who
were not ambulating independently before the stroke event were excluded from the analysis.
Patient’s characteristics such as age, gender, race and insurance status, National Institute
of Health (NIH) stroke scale score, presence of persistent atrial fibrillation or flutter, previous
medical and medication history and nothing per mouth status; event-related characteristics such
as symptom onset to hospital arrival time, day, time and year of admission; and hospital features
including number of beds and location were considered as covariates in the analysis. Based on
their distribution on the basis of number of beds, hospitals were classified as small (<100 beds),
medium-small (100–249 beds), medium-large (250–399 beds) and large hospitals (≥400 beds).
We used the Rural-Urban Commuting Area classification (version 2.0) of location to classify
hospitals geographically into metropolitan (codes 1–3) and nonmetropolitan (codes >3).43 We
assessed patient, hospital and event related characteristics descriptively and tested for differences
between patients who did and did not receive defect-free care using χ2 tests for nominal variables
and Wilcoxon tests for quantitative variables.

Data elements included in the multivariable analyses had missing values in less than 5%
of the observations except for NIH stroke scale which has missing values for 29% of the
observations, respectively. Therefore, we performed multiple imputation with 20 replications
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assuming a general missing pattern and missing at random on data elements included in the
analysis.70 We applied generalized estimating equations (GLIMMIX procedure) to assess the
outcomes controlling for in-hospital correlation and considering hospital as a random variable.

RESULTS

Among the 14,246 acute ischemic stroke patients included in the study, 51.3% were
female, 61.8% were White, and the median age was 69 years (IQR: 58, 80). The three most
common comorbidities were hypertension (82.4%), dyslipidemia (41.1%) and diabetes mellitus
(34.5%). Based on the ten performance measures, 69.1% received defect-free care and on
aggregate patients received 92.8% of the indicated care components. Patients who received
defect-free care had more severe stroke than their counterparts; a relatively higher proportion of
them were also non-ambulating at discharge and died within one year of the incident (Table 7).

Patients with more number of indicated care components were less likely to receive
defect-free care (Figure 2) than those with relatively fewer indicated elements of stroke care.
Moreover, stroke was more severe among patients with fewer indicated care components (Figure
3). Patients with three or fewer indicated care components had a 72.9% 1-year mortality while
those with more than three had a 12.4% 1-year mortality.

The 1-year mortality among patients with a missing value in a predictor variable was
19.1% compared to the 19.7% among those with complete data. On multivariate analyses of the
imputed data, patients who did not receive defect-free care had a 0.87 (95%CI: 0.75, 1.00; pvalue=0.05) lower odds of dying in one year compared to those who received defect-free care.
Moreover, they also had a 0.58 (95%CI: 0.48, 0.67; p-value<0.0001) lower odds of not
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ambulating at discharge. Nonetheless, when quality of stroke care was measured by the
composite indicator, those who received the lowest and intermediate quality of care had higher
odds (OR=3.94; 95%CI: 3.27, 4.75; p-value <0.0001 and OR=1.35; 95%CI: 1.12, 1.62; pvalue=0.002, respectively) of dying within one year compared to those who received the best
quality stroke care. Furthermore, patients with the lowest and intermediate quality care had
statistically significant 5.7 times (95%CI: 4.59, 7.06; p-value<0.0001) and 3.08 (95%CI: 2.53,
3.75; p-value<0.0001) greater odds, respectively, of not ambulating at discharge compared to
their counterparts. (Table 8). Similar results were also documented on complete data analysis.

DISCUSSION

The result of this study shows that acute ischemic stroke patients who received a quality
care had a better long-term outcome. The odds for dying within one year increased progressively
as the quality of care patients received diminished. Similarly, a statistically significant positive
association was documented between the quality of stroke care and patients’ ambulatory status at
discharge.

Contrary to what is expected, patients who did not receive better care, as measured by
defect-free care, appeared to have better outcomes. They had a 13% and a 42% lower odds of
dying in the first year and non-ambulating at discharge, respectively, compared to those who
received defect-free care. Our analysis further revealed that patients with more severe stroke
were eligible to receive fewer number of care components and were more likely to have defectfree care. Although we adjusted for measures of disease acuity, including the NIH stroke scale
score, we cannot vouch that severity is captured fully by the score.
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Compared to the all-or-none scoring of defect-free care, the composite measure captured
intermediate level care quality and gave credit for delivery of some, not necessarily all, of the
indicated care processes. It gave equal weight to each care component and presented quality of
care on a continuous scale rather than as a binary outcome. The impact of each care element on
patient outcome, however, may be different and this may require assigning different weights.

This study has some methodological limitations. Fourteen percent of the initial study
subject were excluded because they did not match records from the hospital discharge data.
Obviously this could introduce bias, namely a non-differential bias because record matching was
not related to the quality of care patients received. Patient without documented symptom onset
time were also excluded, and we imputed for missing values, mainly for NIH stroke scale score,
for a third of the study subjects. This may introduce bias as well; however, the 1-year mortality
weren’t different between patients with and without complete data. Despite these limitations, our
findings were also similar in both the complete and imputed data analyses, indicating that the
bias would only be minimal.

Measuring quality of care is an arduous exercise and requires rigorous examination of
what each measure entails. It involves identifying care components that would have effect on
patient outcome, defining the subset of patient groups who would be eligible, establishing
procedures for delivery and documentation of the care component and determining whether an
eligible patient received the care indicated. It is possible that errors could be introduced at any
step of assessing the quality of care delivery. The error gets compounded when measures of
several quality of care components are aggregated in an all-or-none fashion as in defect-free
care. The composite measure, on the other hand, was not influenced by the number of care
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components indicated for a patient. Error in measurement of one care component could affect
partly the aggregate measure of quality of care. Thus, defect-free care, though a stringent
aggregate indicator for monitoring and improving the process of care delivery, is not the ideal
quality measure when the impact of quality improvement initiatives in stroke care is evaluated.
Although each component of stroke care is backed by scientific evidences,33 it is
important to evaluate their effectiveness in the aggregate, in the context of a quality
improvement initiative. To the best of our knowledge, no study has examined the long-term
effects of hospital-based quality improvement initiative in stroke care. This study assessed both
short and long-term outcomes and showed that patients who received better care had a lower risk
of death, a finding which could expand quality improvement activities across hospitals caring for
stroke patients.

Conclusion

Quality improvement initiatives improve not only the process of care delivery but also
patient outcome. Hospitals should be encouraged to undertake quality improvement activities to
measure and monitor the nationally recommended performance indicators in order to improve
the quality of their stroke patient care.
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Table 6.

Performance measures endorsed by the CDC, the American Heart Association/American
Stroke Association and the Joint Commission

Performance measures
Venous thromboembolism prophylaxis
Administration of antithrombotic medication within 48 hours
Anticoagulant medication for patients with atrial fibrillation
Administration of tissue plasminogen activator (tPA)
Dysphagia screening
Antithrombotic medication at discharge
Prescription of lipid lowering medication
Stroke education
Smoking cessation counseling or treatment
Rehabilitation assessment
Source: MMWR Morb Mortal Wkly Rep. 2011;60(7):206-10.
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Table 7. Characteristics of acute ischemic patients by defect-free care status, Georgia Coverdell Acute
Stroke Registry, 2008–2013
Patient Did
Not Receive
DFCa

Patient
Received
DFCa

P-valueb

Characteristics

Total

Age, median (IQR)

69 (58, 80)

68 (57, 79)

69 (58. 80)

<.0001

Female, n(%)

7,309 (51.3)

2,291 (52.1)

5,018 (51.0)

0.20

Whites, n(%)

8,808 (61.8)

2,828 (64.30)

5,980 (60.7)

<.0001

Medicare health insurance coverage, n(%)

8,497 (59.7)

2,552 (58.1)

5,945 (60.4)

0.01

6 (2, 13)

4 (1, 9)

6 (2, 14)

<.0001

2,936 (20.6)

796 (18.1)

2,140 (21.7)

<.0001

1,323 (9.3)

232 (5.3)

1,091 (11.1)

<.0001

183 (69, 460)

158 (66, 399)

195 (71, 480)

<.0001

483 (3.4)
2,378 (16.7)
3,424 (24.0)
7,961 (55.9)

307 (7.0)
884(20.1)
1,005 (22.9)
2,200 (50.0)

176 (1.8)
1,494 (15.2)
2,419 (24.6)
5,761 (58.5)

10,018 (71.7)
3,958 (28.3)

3,191 (72.6)
1,205 (27.4)

7,097 (72.1)
2,753 (27.9)

0.51

5,217 (36.6)
9,029 (63.4)

1,600 (36.4)
2,796 (63.6)

3,617 (36.7)
6,233 (63.3)

0.71

1,419 (10.0)
1,656 (11.6)
2,231 (15.7)
2,617 (18.4)
3,088 (21.7)
3,235 (22.7)

911 (20.7)
873 (19.9)
600 (13.6)
651 (14.8)
702 (16.0)
659 (15.0)

508 (5.2)
783 (7.9)
1,631 (16.6)
1,966 (20.0)
2,386 (24.2)
2,576 (26.2)

2,775 (19.5)
1,594 (14.0)

672 (15.3)
303 (8.5)

2,103 (21.4)
1,291 (16.5)

NIH stroke scale score (unit), median (IQR)
Atrial fibrillation/flutter, n(%)
Nothing per mouth, n(%)
Last known well to hospital arrival time
(minutes), median(IQR)
Hospital bed size, n(%)
<100 beds
100–249 beds
250–399 beds
>=400 beds
Day of the week,c n(%)
Week day
Weekend
Hour of the day,c n(%)
Night
Day
Calendar year, n(%)
2008
2009
2010
2011
2012
2013
Outcome, n(%)
Death in 1-Year
Not ambulating at discharged
Note:-

IQR = Interquartile range; DFC = Defect-free care
a: Defect-free care: delivery of care meeting all quality indicators for which a patient is eligible
b: chi-square and Wilcoxon tests were applied for nominal and quantitative variables, respectively.
c: refers to the admission day and time
d: among patients who were ambulating prior to the stroke incident
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<.0001

<.0001

<.0001
<.0001

Table 8. Relative risk of 1-year mortality and non-ambulating at discharge among acute ischemic stroke
patients by quality of care, Georgia Coverdell Acute Stroke Registry 2008-2013.
Complete Data
Performance
measure

Death in one year post
incident
Odds Ratio
(95%CI)

P-value

Imputed Data

Not Ambulating at
Dischargea
Odds Ratio

P-value

(95%CI)

Death in one year post
incident
Odds Ratio
(95%CI)

P-value

Not Ambulating at
Dischargea
Odds Ratio
(95%CI)

P-value

Received defect-free
careb
No
Yes
Weighted Composite
Indexc
1st Tertile
2nd Tertile
rd

3 Tertile

0.84
(0.69, 1.02)
Referent

4.10
(3.27, 5.13)
1.28
(1.02, 1.60)
Referent

0.073

<0.0001

0.67
(0.54, 0.82)
Referent

0.0003

6.64
(5.09, 8.66)
3.06
(2.41, 3.89)
Referent

<0.0001

0.87
(0.75, 1.00)
Referent

3.94
(3.27, 4.75)
1.35
(1.12, 1.62)
Referent

0.05

<0.0001
0.002

0.58
(0.48, 0.67)
Referent

5.70
(4.59, 7.06)
3.08
(2.53, 3.75)
Referent

<0.0001

<0.0001
<0.0001

Note:- the estimates are adjusted for age, gender, race and insurance status, National Institute of Health stroke scale score,
presence of persistent atrial fibrillation or flutter, previous medical and medication history and nothing per mouth
status, symptom onset to hospital arrival time, time, day year of admission, hospital number of beds and location.
a: among patients who were ambulating on prior to the stroke incident
b: a patient who received all the indicated care components related to the ten performance measures is labelled to have
had a defect-free care
c: proportion of performance measures weighted by natural logarithm of the total number of indicated care
components; the quality of care improves going from the first to the third tertile
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Figure 1. Flow diagram for patients included in the analysis
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Figure 2. Defect-free care and average composite measure by the number of performance measure acute
ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013

(DFC (defect-free care):
Composite:
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acute ischemic patients were eligible for, Georgia Coverdell Acute Stroke Registry, 2008-2013
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CHAPTER IV

The Impact of Intravenous Alteplase on Long-term Patient Survival: the Georgia
Coverdell Acute Stroke Registry’s Experience
Abstract

Introduction

Intravenous alteplase reduces disability and improves functionality among acute ischemic
stroke patients. Two decades after its approval, only a small fraction of patients get the treatment,
and demonstrating its impact on mortality may make a strong case for its wider use. This study
assessed the impact of thrombolytic treatment by alteplase on 1-year mortality and readmission
among acute ischemic stroke patients.

Method

The 2008-2013 Georgia Coverdell Acute Stroke Registry data were linked with the 20082013 hospital discharge and the 2008-2014 death data in Georgia. Multiple imputation was
applied; a propensity score measuring the probability of receiving intravenous alteplase was
calculated and used for matching. A conditional logistic regression was applied to compare 1year mortality and readmission among propensity score matched pairs.

Results

Overall, 20.3% of 9,620 acute ischemic stroke patients died and 22.4% were readmitted
in one year. The multivariable regression result showed that patients who did not receive IV
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying at one year
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than those who were treated with the thrombolytic agent. Among patients discharged home, no
statistically significant difference was documented in the odds of being readmitted at least once
within 365 days post-stroke discharge.

Discussion and Conclusion

The benefits of intravenous alteplase are not limited to improvement in function or
absence of disability but also in reduction of mortality. The results of this study suggests that
patients who are identified as eligible for intravenous alteplase need to be offered the treatment.

43

INTRODUCTION

Intravenous alteplase was approved in 1996 by FDA as a thrombolytic agent in ischemic
stroke because patients who received the treatment are 30% more likely to have minimal or no
disability at three month after the index incident71 and one year after the index incident.72 Twenty
years later, fewer than 10% of ischemic stroke patients receive the treatment.73,74 Delay in stroke
identification, lack of swift transport to stroke ready facilities, contraindications and warning
symptoms, and indecision to provide intravenous (IV) alteplase by healthcare providers,75,76 may
be associated with low rates of alteplase use.
Demonstration of IV alteplase’s impact on long-term mortality rather than on disability
could make a strong case for its wider use. To date, the few studies designed to assess patient
outcome using mortality have not shown positive results, possibly because of shorter duration of
follow-ups, differential effect of IV alteplase based on stroke severity, and small sample
size.72,77-79 Stroke registries help to monitor and measure patient outcomes in the long-term and
provide data to support the needed research.80 This study is conducted to evaluate the impact of
receiving intravenous thrombolytic treatment on 1-year mortality of stroke patients cared for by
hospitals participating in the Georgia Coverdell Acute Stroke Registry.

METHODS

We conducted a passive follow-up of acute ischemic stroke patients cared for by
hospitals participating in the Georgia Coverdell Acute Stroke Registry (GCASR). The Georgia
Coverdell Acute Stroke Registry is part of the National Paul Coverdell Acute Stroke Program
and is designed to monitor the quality of stroke care in the state.32 The registry has the goal of
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reducing stroke disability, premature mortality and preventing recurrent stroke through
improvement in quality of stroke care in collaboration with the participating hospitals and other
stakeholders.

Data Sources and data linkage

We used the 2008-2013 GCASR data, the 2008-2013 Georgia Discharge Data System
(GDDS) and the 2008-2014 Georgia death data for this study. The GDDS has information on
patients discharged from non-federal acute care hospitals in Georgia. The death data are
collected from death certificates and provide information on deaths of Georgians including those
who passed away in other states. The three data sources were linked stepwise using the FineGrained Record Integration and Linkage software program version 2.1.5.42 First, we linked the
GCASR data with GDDS data using a hierarchical deterministic procedure; the output was,
subsequently, linked with the death data using a probabilistic data linkage approach. We used
hospital code, admission and discharge date, age, race and gender for matching the GCASR data
with GDDS data. Additional information on residence (ZIP code and county) and a 15 digit
alphanumerical code – composed of the first two letters of the first name, the first and last two
letters of last name, birthdate and gender – were added for the probabilistic linkage.

Similar to a previous study, in which the probabilistic linkage between hospital discharge
and death data was seen to have a very good accuracy with 92% sensitivity and 100%
specificity,68 the deterministic linkage in this study had a sensitivity of 87% and positive
predictive value of 96% (details provided as Annex). There were 45,727 records with a clinical
diagnosis of acute ischemic stroke in the initial GCASR data list. Of these, 41,216 were linked
with GDDS data but only 39,331 had LONGID, the data element critical for linking with the
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death data and for determining readmissions from index admission. After excluding the
readmissions, 36,043 subjects were eligible for follow-up (Figure 4).

Inclusion and Exclusion Criteria

In this study, we included only subjects who were eligible for IV alteplase administration.
Based on AHA’s guidelines for the early management of patients with acute ischemic stroke,81
patients with contraindications and warning symptoms and those with spontaneous stroke
symptom recovery or a National Institute of Health (NIH) stroke scale score of zero were
considered ineligible for IV alteplase. We excluded from analysis patients with in-hospital
stroke, symptom onset (last known to be well) to hospital arrival time greater than 270 minutes
or no symptom onset time documented and patients from hospitals with no IV alteplase treated
patients during the study period.

Statistical Analysis

The main outcome of interest was death from any cause within 365 days after index
patients’ admission. Readmission for any cause within 365 days post discharge among patients
discharged home was also assessed as a secondary outcome. Treatment with IV alteplase
documented in the registry was the main predictor of outcome.

Data elements included in the analyses had missing values in less than 5% of the
observations except for NIH stroke scale which had 29% missing values. Altogether, 38% of the
observations had missing value at least for one variable. Therefore, we performed multiple
imputation on 9,620 observations assuming a general missing pattern and missing at random
with twenty replications on variables considered to have relation with receiving IV alteplase and
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patient’s outcome.70 To assess for bias from imputation, we analyzed the data with complete
information as well.

A propensity score measuring the probability of receiving IV alteplase was calculated
using variables that could be related to the decision of administering thrombolytic. Age, gender,
race, Medicare as major source of health insurance, transport to hospital by EMS, last known
well to hospital arrival time, history of other illnesses and medication, severity of patient
condition as documented by NIH stroke scale score and nothing per mouth status, hospital bed
size, hour, day and year of admission were treated as predictors. Hospital bed size and NIH
Stroke Scale score were categorized based on their distribution; hospital bed size was classified
as small (<100 beds), medium-small (101-249 beds), medium-large (250-400 beds) and large
(>400 beds) while the NIH Stroke Score was classified in quartiles (0-4, 5-8, 9-14, and greater
than 14). Hospitals were classified geographically as metropolitan (codes 1-3) and nonmetropolitan (codes >3) based on the Rural-Urban Commuting Area classification (version2.0)
of location.43
We used the propensity score for variable reduction and matching.82 Patients treated with
IV alteplase were matched one-to one with those eligible but didn’t receive the treatment using a
SAS macro program.83 Alteplase treated patients were first matched to controls on 8 digits of the
propensity score. Those that did not match were then matched to controls on 7 digits of the score,
and we continued the matching down to a 1-digit match. The average difference in propensity
score between the matched pairs was less than 0.001.

47

We compared the characteristics of IV alteplase treated and non-treated patients, among
those eligible for the thrombolytic medication and with complete information, using chi-square
test for categorical variables and Wilcoxon test for continuous variables. We compared
outcomes, on imputed data, among propensity score matched pairs using conditional logistic
regression. The analyses were done using the SAS® statistical software version 9.3 (SAS
Institute, Inc.).

RESULTS

The final analytical dataset had 9,620 patients from 48 hospitals with a median age of 68
years (IQR: 57, 80 years). More than half (52%) were female, 60% were white, 59% had
Medicare as their main source of health insurance coverage, and 25.8% received IV alteplase.
The average overall mortality rates documented were 4.6% at 7 days, 10.4% at 30 days, 13.5% at
90 days and 20.3% at one year. Moreover, 22.4% of the patients were readmitted within one year
post discharge. Based on information from patients with complete data (n=2,925), patients
treated with IV alteplase had statistically significantly different features including age, health
insurance coverage, means of transport to hospital, NIH stroke scale score, NPO status and
medication intake prior to admission compared to those who were eligible but didn’t receive the
treatment (Table 9).

The one year mortality among patients with a missing value in a predictor variable was
20.5% compared to the 22.3% among those with complete data. The aggregate conditional
logistic regression result from imputed data showed that patients who did not receive IV
alteplase had a 1.49 (95%CI: 1.09-2.04; p-value=0.01) times higher odds of dying at one year
than those who were treated with the thrombolytic agent (Table 10). The lowest and highest odds
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ratios observed in the twenty replicates were 1.22 and 1.70, respectively. Moreover, the analysis
on complete records (n=348 pairs) showed a result in similar direction albeit statistically not as
significant (p-value=0.37) as the one on imputed data (Table 10). Among patients discharged
home, no statistically significant difference (OR=0.90, 95%CI: 0.59, 1.39, p-value=0.24) was
documented in the odds of being readmitted at least once within 365 days post discharge (Table
2).

DISCUSSION

Acute ischemic stroke patients who were treated with intravenous thrombolysis had a
better odds of survival at one year post discharge. Those who were eligible but didn’t receive
intravenous alteplase had a 49% higher odds of dying at one year than those who received the
thrombolytic agent. The data, however, didn’t show evidence that intravenous thrombolysis
reduces 1-year readmission among patients discharged home.
Prior studies with randomized design haven’t shown a statistically significant reduction
of 1-year mortality for patients treated IV alteplase.72,77-79 The observed difference might be due
to differences in characteristics of study populations. The NINDS study72 applied exclusion
criteria similar to those used in this study, but it included only patients who could be treated
within 3 hours of symptom onset. The third International Stroke Trial (IST) study,77 on the other
hand, included patients who neither had a clear indication nor contraindication for IV alteplase
and who could be treated within 6 hours of symptom onset.

Administration of IV alteplase has its own risk for complication such as bleeding and is
not indicated for all patients who present with acute ischemic stroke. In this study, we considered
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only patients who do not have a condition that may preclude the use of IV alteplase. In a similar
observational study,80 where only eligible patients as defined by national guidelines were
considered, Schmitz et al. reported a similar finding (Hazard Ratio = 1.52; 95% confidence
interval, 1.14–2.04) based on the Danish Stroke Registry.

Some shortcomings are worth considering in the interpretation of the result of this study.
One, aside from the clinical diagnosis, no imaging information was available to differentiate the
type and extent of ischemic insult that may affect patient outcome.84 Two, the data linkage left
out 14% unmatched patient records and could potentially introduce bias. Three, we applied
multiple imputation to get accurate estimates that are generalizable to the study population.
Patients with missing data had a 1-year mortality (20.5%) comparable to those with complete
data (21.3%). Thus, it is reasonable to assume that missingness were at random. Although bias
could potentially be introduced, analysis of complete data produced results similar to the ones
generated from imputed data. Estimates for each replicate datasets from the multiple imputation
also indicated an association between IV alteplase treatment and 1-yr mortality in the same
direction.

This study adds more positive results to the existing literature on the impact of IV
alteplase particularly in the context of its effectiveness and hospitals’ effort to improve the
overall quality of acute stroke care. The results would help healthcare providers make their
decision promptly and save valuable time in the care of stroke patients.
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Conclusions

The results of this study suggest that patients who are eligible be determined as swiftly as
possible and those identified as eligible receive the treatment. Besides improvement in function
and absence of disability, intravenous alteplase administration is associated with reduction in
long-term mortality.
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Table 9. Characteristics of acute ischemic stroke patients eligible for IV alteplase and with
complete information (n=2925), Georgia Coverdell Acute Stroke Registry, 2008-2013.

Characteristics
Age, years, median(IQR)

Treated with
IV
ALTEPLASE
(n=1,937)
68 (57, 79)

Not Treated with
IV ALTEPLASE
(n=988)

p-valuea

71 (61, 81.5)

0.0005

Female, n(%)

990 (51.1)

512 (51.8)

0.72

Whites, n(%)

1,169 (60.4)

632 (64.0)

0.06

Medicare as the principal health insurance
coverage, n(%)

1,108 (57.2)

653 (66.1)

<0.0001

Brought by EMS, n(%)

1,660 (85.7)

683 (69.1)

<0.0001

NIH Stroke scale score, unit, median(IQR)

11 (7, 18)

5 (3, 12)

<0.0001

Persistent or Paroxysmal Atrial
Fibrillation/Flutter, n(%)

472 (24.4)

231 (23.4)

0.55

Nothing per mouth status

317 (16.4)

100 (10.1)

<0.0001

Medication prior to admission, n(%)
Antihypertensive
1,356 (70.0)
766 (77.5)
<0.0001
Lipid lowering drug
760 (39.2)
448 (45.3)
0.002
Medical history of, n(%)
Dyslipidemia
751 (38.8)
436 (44.1)
0.01
Diabetes mellitus
521 (26.9)
339 (34.3)
<0.0001
Hypertension
1,567 (80.9)
835 (84.5)
0.02
Coronary artery disease (MI)
463 (23.9)
258 (26.1)
0.19
Heart failure
207 (10.7)
113 (11.4)
0.54
Atrial fibrillation/flutter
374 (19.3)
186 (18.8)
0.75
Smoking
451 (23.3)
200 (20.2)
0.06
Last known well to hospital arrival time,
60 (40, 88)
191 (120, 230)
<0.0001
minutes, median(IQR)
Hospital bed size, n(%)
<100 beds
30 (1.5)
31 (3.1)
100–249 beds
256 (13.2)
163 (16.5)
0.0009
250–399 beds
422 (21.8)
183 (18.5)
>=400 beds
1,229 (63.4)
611 (61.8)
Admitted on, n(%)
Weekend
540 (27.9)
282 (28.5)
0.71
Day time
1,259 (65.0)
614 (62.1)
0.13
Calendar Year, n(%)
2008
142 (7.3)
197 (19.9)
2009
198 (10.2)
180 (18.2)
2010
306 (15.8)
147 (14.9)
<0.0001
2011
343 (17.7)
140 (14.2)
2012
441 (22.8)
178 (18.0)
2013
507 (26.2)
146 (14.8)
One year Outcome, n(%)
Mortality
424 (21.9)
227 (23.0)
0.50
Readmission
463 (23.9)
233 (23.6)
0.85
Abbreviation: IQR, Interquartile range
a χ2 and Wilcoxon tests were applied for nominal and quantitative variables, respectively.
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Table 10. Relative risk of 1-year mortality and readmission by intravenous alteplase treatment status,
Georgia Coverdell Acute Stroke Registry 2008-2013.
Complete Data
Odds Ratio
(95%CL)

Outcome

Imputed Data

p-value

Odds Ratio
(95%CL)

p-value

1-year Mortality
Didn’t receive IV alteplase
Received IV alteplase

1.12 (0.83,1.67)

0.37

Referent

1.49 (1.09, 2.04)

0.01

Referent

1-year Readmission
Didn’t receive IV alteplase
Received IV alteplase
N.B.:-

0.81 (0.48, 1.38)
Referent

0.44

0.90 (0.59, 1.39)
Referent

CL=Confidence limit; IV=Intravenous
Alteplase treated patients were matched one-to-one with eligible non-treated patients on
probability of receiving IV alteplase (propensity score), and conditional logistic regression applied
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0.64

Figure 4. Flow diagram for patients included in the analysis
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CHAPTER V

SUMMARY

The three studies demonstrated that registry-based quality improvement is an effective
strategy to improve the quality of stroke care. Patients treated at hospitals participating in the
Georgia Coverdell Acute Stroke Registry had a better survival rate than those cared for by
hospitals not participating in the registry. Among patients treated at GCASR participating
hospitals, delivery of a better quality care was associated with a lower 1-year mortality.
Moreover, acute ischemic stroke patients who received intravenous alteplase had a lower
mortality rate compared to those who were eligible but didn’t receive the treatment.
In the past two decades, the management of acute stroke has been continuously changing.
The approval for clot busting drug use in ischemic stroke has revolutionized the treatment
paradigm from simple palliative care to prevention of death and disability, and control of risk
factors. But with each scientific discovery to ameliorate the untoward effects of stroke incident
comes the need for making the new treatment available for patients. Currently, there is a gap
between what is known as the best care and what is actually being practiced by healthcare
providers. The national institute of neurological disorders and stroke, in fact, has identified
translation of scientific discovery as a priority area for its action.

Researchers have highlighted that the strategy of knowledge translation has evolved from
a simple passive diffusion where published scientific discoveries are expected to be read,
understood and assimilated in routine care delivery by practitioners to quality improvement and
system change.9 In line with this, GCASR, funded by the CDC, adopted the strategy of
monitoring the quality of stroke care using performance measures. Hospitals modified care
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processes in their effort to raise their performance measures, and thus improving the quality of
care stroke patients receive. Performance measures have their own short comings, even when
there is agreement on what to measure, in terms of complexity of algorithm, clarity of definition
of data elements feeding to the performance measure, data quality and validity of the measure.
Nevertheless, they indicate, on average, the quality of care delivered to stroke patients by a
healthcare facility.

Performance measures are process indicators and are meant to display quality of service
at hospital level. They serve for monitoring quality improvement efforts and the progress
achieved in improving the process of care delivery. In these studies, however, they are also used
to measure quality of care at a patient level to assess patient outcome. Understandably, the
results indicate that process indicators may not necessarily capture the essence of quality of care
adequately to serve as a proxy measure in analyzing impact. Therefore, it is imperative in any
evaluation of impact of quality of care, appropriate measures are used to capture quality in the
first place.

Quality is an abstract concept which cannot be measured directly. The Institute of
Medicine outlines specific components that constitute quality in a clinical care: safety,
effectiveness, patient-centeredness, timeliness, efficiency, and equitability.85 It is an arduous
effort to develop an indicator that encompasses all these aspects of quality in one. Nevertheless,
there are statistical techniques that would serve to define abstract constructs such as “quality”
using indicator variables. Therefore, it will be a worthwhile effort to develop latent models using
either performance measures or any additional patient level information to classify whether a
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patient, in fact, has received a quality care rather than just adding each performance measure or
apply an all-or-none rule to measure quality.

Time is a critical element in the management of stroke patients, and emergency medical
services play a significant role in identifying and transporting stroke patients to stroke ready
hospitals. Moreover, how they handle patients with a presumptive diagnosis of stroke has its
bearing on the subsequent in-hospital care and on patients’ outcome. There are care processes
that need to be aligned with evidence-based best practices. On the other hand, stroke is an
overwhelming experience both for patients and their caregivers. Once patients are discharged,
they require regular follow-ups, either for rehabilitation services or simply to ensure that they
adhere to the guideline they receive at discharge. Efforts are being made to develop evidence
based clinical guidelines on the post-hospital care of stroke patients, and there will be a room for
quality improvement as a strategy to bring those best practices to patient fruition. Thus, it will be
necessary to evaluate effectiveness of quality improvement efforts both in the pre-hospital and
post-hospital settings.

Quality improvement in stroke care is not one single intervention; rather it is a
multifaceted strategy and comprises of several activities each one with its own effectiveness,
fidelity in implementation, efficiency, reach and impact on patient outcome. It is critical,
therefore, to identify elements that are core to the strategy before contemplating to scale-up
quality improvement to other stroke care facilities or disease conditions. Evaluating a quality
improvement initiative also requires determining which aspect, which system change, or process
or outcome should be examined. Given the readily availability of data sources, end results such
as mortality, disability and readmission give the opportunity to capture the ultimate impact of
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quality improvement program without discerning how much is contributed by which component.
These studies, therefore, serve as examples and could be replicated for similar initiatives around
any disease condition.
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ANNEX

Linkage Between The Georgia Coverdell Acute Stroke Registry And The Georgia
Discharge Data System

The Georgia Coverdell Acute Stroke Registry (GCASR) data has only non-specific information
including age, sex, race, date of admission and discharge, and facility code. It has about 200
variables and more than 10,000 observations per year. It is assumed that the non-specific
information listed would be sufficient to get a reasonably acceptable yield when the registry is
linked to hospital discharge (GDDS) data.

The hospital discharge data are collected for administrative purpose on all patients who are
hospitalized in non-federal acute care or critical access hospitals in the state of Georgia. The data
set has about 75 variables and more than a million observations per year. Among the hospital
discharges, more than fifty thousand are for adults 18 years and older with an ICD 9 code of
stroke (430-438) in one of the ten diagnosis fields.

The GCASR and GDDS data do not have a universal patient identifier in common; exact
matching of several linking variables applied all at once would have insufficient yield because of
missing values (Table 1) and possible transcription errors. Thus, we applied a hierarchical
deterministic method with different combinations of the linking variables to maximize linkage
accuracy and yield while reducing the impact of missing values and errors (Table 2).

The underlying assumption for linking the GCASR and GDDS data is that no two subjects with
similar demographic characteristics would be admitted to or discharged from the same facility on
the same date with acute stroke (Table 3). Once the two data sets were linked, a 15 digit
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alphanumerical code in the GDDS data, composed of letters from first and last name, birthdate
and gender code, served as a quasi-unique identifier for each subject.

Testing Linkage Accuracy

We used records from the 2010 GCASR and GDDS data for assessing linkage accuracy. In 2010,
56 GCASR facilities had 11,043 acute stroke admissions. The highest number of admissions per
facility per day was nine, and 47 hospitals had admitted two or more patients on the same day at
least once. Among the 2010 discharges from non-federal and non-rehab facilities, 52,272 records
of adults 18 years and older had an ICD 9 code of stroke (430-438) in one of the diagnosis fields
and were used for linkage with the GCASR data.

The registry data is a subset of GDDS data and any subject from GDDS data with similar values
in the six listed matching characteristics – facility, dates of admission and discharge, age, gender
and race – would match with the registry data. It is, thus, appropriate and more informative to
ask how many of the registry data failed to link and whether the linked GCASR records matched
to the true hospital discharge record.

In 2010, about 70% of acute stroke patients in Georgia were treated at GCASR participating
hospitals.1 Assuming an 80% case ascertainment completion rate, the prevalence of GCASR
reported acute stroke admission in Georgia would be greater than fifty percent. Hence, based on
the method described by Buderer,2 a sample of 277 subject would be enough to establish a
sensitivity of 90% with 5% precision at 0.05 level of significance. Considering a two-third
response rate, we increased the sample size to 430.
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Hospitals around the Atlanta metro area account for about half ( 52%) of the registry patients.
Patient records were selected randomly from Atlanta area hospitals with 200 or more discharges
of acute stroke in 2010. The first and last name, sex and birth date of sampled patients were
recorded from the original hospital patient chart. The information was then used to construct the
quasi-unique patient identifier (variable LONGID) that was subsequently compared with the
same variable from the hospital discharge in the linked data file. The difference in the values of
sex (between what was initially entered into the registry data and the one reported by hospitals
for sampled patients) was calculated to quantify simple transcription error in data entry. The
performance of the data linkage between the GCASR and hospital discharge data was assessed
among the randomly selected patients’ records using indices of sensitivity and positive predictive
value. The proportions of registry records linked with GDDS data was analyzed in aggregate and
separately for each hospital. The Fine–grained record integration and linkage tool (FRIL)
software version 2.1.5 was used for data linkage.3

Results

GCASR had 11,043 records entered from 56 hospitals in 2010; 151 were transferred to another
facility without admission. Among the 10,892 records, 10,536 had valid values of all the
variables used for data linkage. Eighteen records had missing value for sex and 340 for race.
Two hundred thirty-five patients were discharged within 24 hours. The matching algorithm
resulted in linking 9,530 (88%) of the GCASR records with hospital discharges (Figure 1).
Concordance in matching variables was greater than 96% between the two data sources (Table
4).
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The proportion of linked records varied among hospitals participating in GCASR from 25% to
99%, the median being 91% with 76% and 94% first and third quartiles, respectively. Though
not statistically significant, differences were observed among hospitals based on bed size and
primary stroke center status (Table 5). Large hospitals and primary stroke centers had a relatively
higher proportion of records matched with the GDDS data.

Information was gathered for 322 the randomly selected GCASR records. Sex and age were
different from what was reported in the registry in 13 and 19 of the sampled records,
respectively. Linkage resulted in 277 (99.6%) true matches and 1 (0.4%) mismatch; the
remaining 44 were not linked to any record from the hospitalization data (Figure 1). The
percentage of matched records varied among hospitals with a median of 92% (Q1=86%,
Q3=96%).

Discussion

Results from the study showed that linkage between the registry and GDDS is highly specific.
There was only one registry record mismatched with the hospital discharge. Examination of the
record indicated a typographical error where an age 57 was entered instead of 75. The yield, on
the other hand, is not comparable to the specificity. Nonetheless, given the percent of missing
values (e.g. 3.3% race in the registry data) and data entry error (e.g. 5% age in registry data)
observed in matching variables, the result can be considered satisfactorily high.
Given a 92% sensitivity in a previous study linking GDDS data with death data,4 the yield
diminishes further when all the three data sources are linked together. We would expect to have
about 80% (0.91x0.88) yield if we combine the registry data with GDDS and then with the death
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records. If we are interested in estimating the occurrence of events such as death among patients
admitted with stroke, we will underestimate the mortality rate. However, if a study aims to assess
the impact of an intervention, for instance IV tPA treatment, and we compare those who received
the treatment vis-à-vis those who didn’t, then it is possible to compare mortality rates between
the two groups, unless there is a reason to believe death in the two groups is captured differently
by death record. Obviously, there will be a misclassification bias but it will be non-differential
and will only diminish the effect measure towards the null value.

The small subset of randomly selected GCASR records showed that matching variables could
have data entry errors. Depending on the number of variables used for matching, applying exact
matching in each linking variable would diminish the yield significantly. Therefore, it is
pragmatic to establish an iterative matching using a couple of blocking variables to maximize the
return at the end of data linkage. The approach used in this study, the hierarchical deterministic
linkage, becomes a necessity rather than a choice.
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Table 1 Percent of missing or implausible values in matching variables among the data sources
Variable

GDDS
(2010)

GCASR
Data

Variable

GDDS
(2010)

Sex

0.0%

0.2%

LONGID

1.6%

Age

0.0%

0.0%

Birth date

0.0%

Race

0.0%

3.3%

Residence County

4.3%

Facility

0.0%

0%

Residence ZIP

4.3%

Discharge date

0.0%

0%

Admission date

0.0%

1.4%

GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System

Table 2 Key variables and their combination for matching the 2010 GCASR and GDDS data
Linkage
Step
Step I

Step II

Step III

Step IV

Step V

N.B.:•
•
•

Linking variable

Distance metric
(Approve/Disapprove level)

Facility
Admission date
Age
Sex
Facility
Admission date
Age
Race
Facility
Discharge date
Age
Sex
Facility
Discharge date
Age
Race

Equal fields Boolean distance
Date Distance (+/- 0 day)
Numeric distance (+/- 0)
Equal fields Boolean distance

Facility
Admission date
Discharge date
Race
Sex

Equal fields Boolean distance
Date Distance (+/- 0 day)
Date Distance (+/- 0 day)
Equal fields Boolean distance
Equal fields Boolean distance

Equal fields Boolean distance
Date Distance (+/- 0 day)
Numeric distance (+/- 0)
Equal fields Boolean distance
Equal fields Boolean distance
Date Distance (+/- 0 day)
Numeric distance (+/- 0)
Equal fields Boolean distance
Equal fields Boolean distance
Date Distance (+/- 0 day)
Numeric distance (+/-0)
Equal fields Boolean distance

Facility is the blocking variable
GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System
Exclude those with
– Missing admission date
– Age differences > 1yr
– Admission date difference > 1 day
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Acceptance
level
100%

100%

100%

100%

100%

Table 3 Specificity of combinations of facility, demographic and event related information
Combination

Total

Unique

Non-specific

GCASR data (N = 11,043)
Facility, Admission date, Age

10,881

10,723

158

Facility, Admission date, Age, Race

10,943

10,844

99

Facility, Admission date, Age, Sex

10,962

10,884

78

Facility, Admission date, Age, Race, Sex

10,991

10,940

51

Facility, Admission date, Age, Race, Sex,
Discharge date

11,023

11,003

20

GDDS data (N = 52,272)
Facility, Admission date, Age

50,855

49,482

1,373

Facility, Admission date, Age, Race

51,405

50,549

856

Facility, Admission date, Age, Sex

51,531

50,804

727

Facility, Admission date, Age, Race, Sex

51,838

51,407

431

Facility, Admission date, Age, Race, Sex,
Discharge date

52,218

52,164
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GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System

Table 4 Agreement in matching variables

Matching Variable

2010 GCASR Vs. GDDS

NAME*

98.4%

Birth Date

98.4%

Age

98.4%

Sex

99.3%

Race

96.7%

Facility

100.0%

Admission date

96.2%

Event/Discharge date

97.1%

GCASR: Georgia Coverdell Acute Stroke Registry; GDDS: Georgia Discharge Data System
*: refers to a 6-digit code derived from names
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Table 5 Average percentages of GCASR records matched with hospital discharges by hospital
characteristics
Categories

Median

1st. Quartile

3rd. Quartile

Bed size
<= 100 beds
101-250 beds
251 - 400 beds
> 400 beds

79.6%
87.0%
92.4%
91.1%

65.6%
70.6%
90.9%
87.9%

91.9%
94.9%
95.0%
93.9%

Primary Stroke Center Status
PSC
Non-PSC

92.0%
82.9%

87.0%
66.9%

94.8%
93.4%

GCASR: Georgia Coverdell Acute Stroke Registry; PSC: Primary Stroke Center

What is missing is
Change the reference numbers in the text
Change the expression for composite measure in the second manuscript
Finalize the list of tables and figures
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Figure 1. Georgia Coverdell Acute Stroke Registry Records linked with Hospital Discharge data, 2010

